AP NEWS

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H1 2018 - ResearchAndMarkets.com

June 6, 2018

DUBLIN--(BUSINESS WIRE)--Jun 6, 2018--The “End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.

The pipeline guide provides a snapshot of the global therapeutic landscape of End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones).

The pipeline guide reviews pipeline therapeutics for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones).

Companies Mentioned

CTI BioPharma Corp Novartis AG Prolong Pharmaceuticals LLC VESSL Therapeutics Ltd

Key Topics Covered

Introduction Report Coverage End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Companies Involved in Therapeutics Development CTI BioPharma Corp Novartis AG Prolong Pharmaceuticals LLC VESSL Therapeutics Ltd End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drug Profiles Cell Therapy for Peripheral Arterial Disease and End-Stage Kidney Disease - Drug Profile Product Description Mechanism Of Action R&D Progress pacritinib - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Plasma Gelsolin Replacement for Renal Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Sanguinate - Drug Profile Product Description Mechanism Of Action R&D Progress tesidolumab - Drug Profile Product Description Mechanism Of Action R&D Progress End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation

For more information about this report visit https://www.researchandmarkets.com/research/pcvmhb/endstage_kidney?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180606005595/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Liver and Kidney Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/06/2018 06:50 AM/DISC: 06/06/2018 06:51 AM

http://www.businesswire.com/news/home/20180606005595/en

AP RADIO
Update hourly